
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is well positioned to continue its growth trajectory with its strong portfolio of precision diagnostics and radiopharmaceuticals, as well as its strategic partnerships. The recent retirement of the CEO has not had a significant impact on the company's operations, and the incoming CEO will have a solid foundation to build upon with a diversified set of products and a stable financial outlook. Additionally, with the recent approval of Pylarify and upcoming catalysts, such as the transition to TruVu and potential for future product approvals and partnerships, Lantheus Holdings has the potential for strong revenue and profit growth in the coming years.
Bears say
Lantheus Holdings is heavily dependent on the success and sustained use of its leading products, DEFINITY and PYLARIFY, which currently make up over 80% of total sales. However, with increased competition in the marketplace and the potential for major disruptions to the company's commercial footprint and manufacturing capabilities, there are significant risks to continued growth and stability. Additionally, reductions in coverage and reimbursement from third-party payors could significantly impact demand for the company's products.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares